These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 3163515)

  • 1. Mechanism of actinomycin D-induced resistance in Ridgway osteogenic sarcoma: an ultrastructural study.
    Kamel HM; Merry S; Toner PG
    J Submicrosc Cytol Pathol; 1988 Jan; 20(1):225-35. PubMed ID: 3163515
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative antitumor activity of actinomycin analogs in mice bearing Ridgway osteogenic sarcoma or P388 leukemia.
    Rose WC; Trader MW; Laster WR; Schabel FM
    Cancer Treat Rep; 1978 May; 62(5):779-89. PubMed ID: 77730
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disposition of [3H]actinomycin D in tumor-bearing mice.
    Galbraith WM; Mellett LB
    Cancer Res; 1976 Apr; 36(4):1242-5. PubMed ID: 1063063
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Actinomycin D: effects on Ridgway osteogenic sarcoma in mice.
    Schwartz HS; Sodergren JE; Sternberg SS; Philips FS
    Cancer Res; 1966 Sep; 26(9):1873-9. PubMed ID: 5224225
    [No Abstract]   [Full Text] [Related]  

  • 5. The enhanced response of the Ridgway osteogenic sarcoma to roentgen radiation combined with actinomycin D.
    D'Angio GJ; Maddock CL; Farber S; Brown BL
    Cancer Res; 1965 Aug; 25(7):1002-7. PubMed ID: 5214993
    [No Abstract]   [Full Text] [Related]  

  • 6. Antitumor effect of actinomycin D entrapped in liposomes bearing subunits of tumor-specific monoclonal immunoglobulin M antibody.
    Hashimoto Y; Sugawara M; Masuko T; Hojo H
    Cancer Res; 1983 Nov; 43(11):5328-34. PubMed ID: 6616468
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resistance patterns of Walker carcinosarcoma 256 and other rodent tumors to cyclophosphamide and L-phenylalanine mustard.
    Schmid FA; Otter GM; Stock CC
    Cancer Res; 1980 Mar; 40(3):830-3. PubMed ID: 7471099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of lipid vesicles as carriers to introduce actinomycin D into resistant tumor cells.
    Papahadjopoulos D; Poste G; Vail WJ; Biedler JL
    Cancer Res; 1976 Sep; 36(9 pt.1):2988-94. PubMed ID: 975068
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Actinomycin D causes multidrug resistance and differentiation in a human rhabdomyosarcoma cell line.
    Melguizo C; Prados J; Fernández JE; Vélez C; Alvarez L; Aránega A
    Cell Mol Biol (Noisy-le-grand); 1994 Mar; 40(2):137-45. PubMed ID: 7911694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circumvention of pleiotropic drug resistance in subcutaneous tumours in vivo with verapamil and clomipramine.
    Merry S; Hamilton TG; Flanigan P; Freshney RI; Kaye SB
    Eur J Cancer; 1991; 27(1):31-4. PubMed ID: 1826436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergy is achieved by complementation with Apo2L/TRAIL and actinomycin D in Apo2L/TRAIL-mediated apoptosis of prostate cancer cells: role of XIAP in resistance.
    Ng CP; Zisman A; Bonavida B
    Prostate; 2002 Dec; 53(4):286-99. PubMed ID: 12430140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and actinomycin D induces apoptosis even in TRAIL-resistant human pancreatic cancer cells.
    Matsuzaki H; Schmied BM; Ulrich A; Standop J; Schneider MB; Batra SK; Picha KS; Pour PM
    Clin Cancer Res; 2001 Feb; 7(2):407-14. PubMed ID: 11234897
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A phase I/II dose escalation and activity study of intravenous injections of OCaP1 for subjects with refractory osteosarcoma metastatic to lung.
    Benjamin R; Helman L; Meyers P; Reaman G
    Hum Gene Ther; 2001 Aug; 12(12):1591-3. PubMed ID: 11529247
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intrinsic drug resistance in a human lung carcinoma xenograft is associated with overexpression of multidrug-resistance DNA-sequences and of plasma membrane glycoproteins.
    Volm M; Bak M; Mattern J
    Arzneimittelforschung; 1988 Aug; 38(8):1189-93. PubMed ID: 3196414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Relation of mammalian cell resistance to actinomycin D with a change in the karyotype and a decrease in cytoplasmic membrane permeability].
    Massino IuS; Kakpakova ES; Kopnin BP; Pogosiants EE
    Genetika; 1981; 17(7):1253-8. PubMed ID: 7196855
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Actinomycin-D-resistant in vitro mouse cell line derived from a methylcholanthrene-induced sarcoma: decrease of malignancy and antigenic characteristics.
    Belehradek J; Biedler JL; Thonier M; Barski G
    Int J Cancer; 1974 Dec; 14(6):779-88. PubMed ID: 4142788
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment of tumour bearing mice with liponsome-entrapped actinomycin D prolongs their survival.
    Gregoriadis G; Neerunjun ED
    Res Commun Chem Pathol Pharmacol; 1975 Feb; 10(2):351-62. PubMed ID: 1153840
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Studies on the mechanism of drug resistance in tumor cells and a new antitumor antibiotic].
    Tanaka N
    Gan To Kagaku Ryoho; 1984 Dec; 11(12 Pt 2):2666-73. PubMed ID: 6210060
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nitroxide tempo, a small molecule, induces apoptosis in prostate carcinoma cells and suppresses tumor growth in athymic mice.
    Suy S; Mitchell JB; Samuni A; Mueller S; Kasid U
    Cancer; 2005 Mar; 103(6):1302-13. PubMed ID: 15685617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rapid killing of actinomycin D-treated tumor cells by human mononuclear cells. I. Effectors belong to the monocyte-macrophage lineage.
    Colotta F; Peri G; Villa A; Mantovani A
    J Immunol; 1984 Feb; 132(2):936-44. PubMed ID: 6690624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.